RBC Capital Mkts initiated coverage on Alkermes Plc with a new price target
$ALKS
Biotechnology: Pharmaceutical Preparations
Health Care
RBC Capital Mkts initiated coverage of Alkermes Plc with a rating of Sector Perform and set a new price target of $40.00